Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.
Cancers
Collins, Denis M DM; Conlon, Neil T NT; Kannan, Srinivasaraghavan S; Verma, Chandra S CS; Eli, Lisa D LD; Lalani, Alshad S AS; Crown, John J